FR4384M - - Google Patents

Info

Publication number
FR4384M
FR4384M FR19843A FR19843A FR4384M FR 4384 M FR4384 M FR 4384M FR 19843 A FR19843 A FR 19843A FR 19843 A FR19843 A FR 19843A FR 4384 M FR4384 M FR 4384M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR19843A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to FR19843A priority Critical patent/FR4384M/fr
Application granted granted Critical
Publication of FR4384M publication Critical patent/FR4384M/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
FR19843A 1965-06-08 1965-06-08 Expired FR4384M (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR19843A FR4384M (en) 1965-06-08 1965-06-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR19843A FR4384M (en) 1965-06-08 1965-06-08

Publications (1)

Publication Number Publication Date
FR4384M true FR4384M (en) 1966-08-29

Family

ID=85686376

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19843A Expired FR4384M (en) 1965-06-08 1965-06-08

Country Status (1)

Country Link
FR (1) FR4384M (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004814A2 (en) * 1985-02-19 1986-08-28 Board Of Regents, The University Of Texas System Osteoporosis inhibition by dietary calcium supplementation
WO1986004815A2 (en) * 1985-02-19 1986-08-28 Board Of Regents, The University Of Texas System Liquid dietary calcium supplementation
US4814177A (en) * 1986-03-18 1989-03-21 Board Of Regents, University Of Texas System Ultradense and more soluble and bioavailable preparations of calcium citrate
US4851221A (en) * 1985-02-19 1989-07-25 Mission Pharmacal Company Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid
US5314919A (en) * 1987-08-28 1994-05-24 The Procter & Gamble Company Calcium supplements

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004814A2 (en) * 1985-02-19 1986-08-28 Board Of Regents, The University Of Texas System Osteoporosis inhibition by dietary calcium supplementation
WO1986004815A2 (en) * 1985-02-19 1986-08-28 Board Of Regents, The University Of Texas System Liquid dietary calcium supplementation
WO1986004815A3 (en) * 1985-02-19 1986-11-06 Univ Texas Liquid dietary calcium supplementation
WO1986004814A3 (en) * 1985-02-19 1986-11-06 Univ Texas Osteoporosis inhibition by dietary calcium supplementation
US4772467A (en) * 1985-02-19 1988-09-20 Board Of Regents, U T Systems Osteoporosis inhibition by dietary calcium supplementation
AU578139B2 (en) * 1985-02-19 1988-10-13 Board Of Regents, The University Of Texas System Osteoporosis inhibition by dietary calcium supplementation
US4851221A (en) * 1985-02-19 1989-07-25 Mission Pharmacal Company Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid
US4814177A (en) * 1986-03-18 1989-03-21 Board Of Regents, University Of Texas System Ultradense and more soluble and bioavailable preparations of calcium citrate
US5314919A (en) * 1987-08-28 1994-05-24 The Procter & Gamble Company Calcium supplements

Similar Documents

Publication Publication Date Title
FR4384M (en)
FR4845M (en)
JPS442631Y1 (en)
JPS437921Y1 (en)
JPS4215996Y1 (en)
JPS447905Y1 (en)
BE673732A (en)
NL6611333A (en)
BE674829A (en)
BE674752A (en)
BE674704A (en)
BE674553A (en)
NL6502352A (en)
NL6504569A (en)
BE674419A (en)
BE674362A (en)
BE674274A (en)
BE674208A (en)
BE674077A (en)
BE673791A (en)
NL6515492A (en)
BE673790A (en)
BE673764A (en)
BE673763A (en)
BE673232A (en)